The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy
Open Access
- 19 August 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (16) , e7465
Abstract
Background: Concomitant high‐dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin‐induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants.Methods: Conducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty‐one SNPs that were previously associated with CIHL or other cisplatin‐induced toxicities were identified and incorporated into the model. The primary outcome measured was the change in decibels at posttreatment 1‐2‐4 kHz hearing levels per additional minor allele of these SNPs, evaluated using linear mixed‐effects regression models. The model's predictive accuracy was determined by the area under the curve (AUC) using 10‐fold cross‐validation.Results: The rs2289669 SNP in the SLC47A1/MATE1 gene was linked to a significant 2.67 dB increase in hearing loss per allele (95% CI 0.49–4.86, p = 0.017). Incorporating rs2289669 improved the model's AUC from 0.78 to 0.83, a borderline significant improvement (p = 0.073).Conclusions: This study underscores the importance of the rs2289669 SNP in CIHL and demonstrates the potential of combining genetic and clinical data for enhanced predictive models in personalized treatment strategies.Keywords
This publication has 35 references indexed in Scilit:
- Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossNature Genetics, 2015
- Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literatureHead & Neck, 2014
- Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in ChildrenClinical Pharmacology & Therapeutics, 2013
- Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Pharmacogenomics of Cisplatin-Induced OtotoxicityPharmacogenomics, 2011
- Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicityBiochemical Pharmacology, 2010
- Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trialCancer, 2010
- Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective InterventionsThe American Journal of Pathology, 2010
- Cisplatin Ototoxicity and Protection: Clinical and Experimental StudiesThe Tohoku Journal of Experimental Medicine, 2009
- Audiometric Patterns in Ototoxicity of Intra-Arterial Cisplatin Chemoradiation in Patients with Locally Advanced Head and Neck CancerAudiology and Neurotology, 2006